Barclays PLC grew its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 101.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 342,973 shares of the company’s stock after buying an additional 172,745 shares during the period. Barclays PLC’s holdings in Allogene Therapeutics were worth $959,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Perceptive Advisors LLC purchased a new stake in Allogene Therapeutics during the second quarter valued at approximately $6,349,000. Lynx1 Capital Management LP acquired a new position in shares of Allogene Therapeutics during the second quarter worth $5,192,000. Renaissance Technologies LLC lifted its holdings in shares of Allogene Therapeutics by 340.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after purchasing an additional 1,351,055 shares during the last quarter. Zacks Investment Management acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter worth $1,446,000. Finally, Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after buying an additional 507,021 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.
Allogene Therapeutics Price Performance
NASDAQ ALLO opened at $1.92 on Wednesday. The company has a fifty day moving average of $2.30 and a 200 day moving average of $2.53. The company has a market capitalization of $402.57 million, a PE ratio of -1.23 and a beta of 0.86. Allogene Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $5.78.
Analyst Upgrades and Downgrades
Get Our Latest Report on Allogene Therapeutics
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Featured Articles
- Five stocks we like better than Allogene Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Find and Profitably Trade Stocks at 52-Week Lows
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Dividend Payout Ratio Calculator
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report).
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.